Aurobindo Pharma arm gets MHRA marketing nod for biosimilar 

Aurobindo Pharma subsidiary CuraTeQ Biologics has received marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar version Dazublys.

In July, it had received marketing authorisation in the European Union from the European Commission (EC) for the biosimilar indicated for breast cancer. It is CuraTeQ’s fourth biosimilar to be approved by MHRA after Bevqolva in December 2024 and Zefylti in May 2025 and Dyrupeg in June 2025, Aurobindo Pharma said on Tuesday. The parent company’s shares closed 2.07% lower at ₹1,045.30 apiece on the BSE.